Form 13-F position report

SUPERNUS PHARMACEUTICALS

Reported by ASHFORD CAPITAL MANAGEMENT INC

SUPN CUSIP 868459108 Manager CIK 0000897070

Reported 616,986 shares, up 3,203 (0.5%) from the prior quarter.

Reported value -7.0%; share count 0.5% vs. the prior quarter.

Added
% of reported 13F value 2.87% This manager · Q3 2026
Shares 616,986 Quarter-end amount reported
Reported value $26,555,077 Fair value at quarter end
Consecutive quarters held 48 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 30779000
2022-03-31 36341000
2022-06-30 32663000
2022-09-30 37047000
2022-12-31 33310430
2023-03-31 33402683
2023-06-30 27838897
2023-09-30 25274715
2023-12-31 23918563
2024-03-31 26041791
2024-06-30 19043165
2024-09-30 16963011
2024-12-31 19735224
2025-03-31 18554709
2025-06-30 18104205
2025-09-30 26940083
2025-12-31 30443139
2026-03-31 33359744
2026-06-30 28547047
2026-09-30 26555077

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for SUPERNUS PHARMACEUTICALS held by ASHFORD CAPITAL MANAGEMENT INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 616,986 +3,203 (0.5%) 2.87% $26,555,077 2026-11-13
Q2 2026 Reduced 613,783 -31,598 (-4.9%) 3.06% $28,547,047 2026-08-21
Q1 2026 Added 645,381 +32,843 (5.4%) 4.12% $33,359,744 2026-05-15
Q4 2025 Added 612,538 +48,820 (8.7%) 3.39% $30,443,139 2026-02-17
Q3 2025 Reduced 563,718 -10,654 (-1.9%) 3.0% $26,940,083 2025-11-14
Q2 2025 Added 574,372 +7,816 (1.4%) 2.13% $18,104,205 2025-08-18
Q1 2025 Added 566,556 +20,781 (3.8%) 2.39% $18,554,709 2025-05-15
Q4 2024 Added 545,775 +1,740 (0.3%) 2.33% $19,735,224 2025-02-18
Q3 2024 Reduced 544,035 -167,859 (-23.6%) 2.12% $16,963,011 2024-11-18
Q2 2024 Reduced 711,894 -51,571 (-6.8%) 2.57% $19,043,165 2024-08-15
Q1 2024 Reduced 763,465 -63,023 (-7.6%) 3.52% $26,041,791 2024-05-15
Q4 2023 Reduced 826,488 -90,259 (-9.8%) 3.2% $23,918,563 2024-02-15
Q3 2023 Reduced 916,747 -9,364 (-1.0%) 3.72% $25,274,715 2023-11-15
Q2 2023 Added 926,111 +4,149 (0.5%) 3.89% $27,838,897 2023-08-14
Q1 2023 Reduced 921,962 -11,888 (-1.3%) 5.0% $33,402,683 2023-05-15
Q4 2022 Reduced 933,850 -160,593 (-14.7%) 5.17% $33,310,430 2023-02-15
Q3 2022 Reduced 1,094,443 -34,984 (-3.1%) 5.65% $37,047,000 2022-11-16
Q2 2022 Added 1,129,427 +5,022 (0.4%) 4.64% $32,663,000 2022-08-15
Q1 2022 Added 1,124,405 +68,875 (6.5%) 3.91% $36,341,000 2022-05-16
Q4 2021 Added 1,055,530 +38,865 (3.8%) 3.07% $30,779,000 2022-02-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

363 managers reported SUPERNUS PHARMACEUTICALS for Q3 2026.

Managers reporting SUPERNUS PHARMACEUTICALS in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 9,958,165 +608,119 < 0.01% $428,599,422 9 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 3,285,465 -19,964 < 0.01% $141,406,414 3 qtrs
STATE STREET CORPORATION Added 2,569,141 +109,313 < 0.01% $110,575,829 54 qtrs
ARMISTICE CAPITAL LLC Reduced 2,548,000 -98,201 1.34% $109,665,920 28 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 2,522,690 +5,969 < 0.01% $108,576,578 3 qtrs
MILLENNIUM MANAGEMENT LLC Reduced 1,973,567 -1,879,645 0.03% $84,942,324 54 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 1,842,308 -235,782 0.01% $79,298,452 46 qtrs
Rubric Capital Management LP New 1,739,892 +1,739,892 0.7% $74,884,952 1 qtr
Stephens Investment Management Group LLC Added 1,638,047 +152,226 0.76% $70,501,543 36 qtrs
TWO SIGMA INVESTMENTS LP Added 1,626,367 +441,989 0.05% $69,998,836 19 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
616,986
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.